» Articles » PMID: 12513992

Coevolution of Bacteriophage PP01 and Escherichia Coli O157:H7 in Continuous Culture

Overview
Date 2003 Jan 7
PMID 12513992
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction between Escherichia coli O157:H7 and its specific bacteriophage PP01 was investigated in chemostat continuous culture. Following the addition of bacteriophage PP01, E. coli O157:H7 cell lysis was observed by over 4 orders of magnitude at a dilution rate of 0.876 h(-1) and by 3 orders of magnitude at a lower dilution rate (0.327 h(-1)). However, the appearance of a series of phage-resistant E. coli isolates, which showed a low efficiency of plating against bacteriophage PP01, led to an increase in the cell concentration in the culture. The colony shape, outer membrane protein expression, and lipopolysaccharide production of each escape mutant were compared. Cessation of major outer membrane protein OmpC production and alteration of lipopolysaccharide composition enabled E. coli O157:H7 to escape PP01 infection. One of the escape mutants of E. coli O157:H7 which formed a mucoid colony (Mu) on Luria-Bertani agar appeared 56 h postincubation at a dilution rate of 0.867 h(-1) and persisted until the end of the experiment (approximately 200 h). Mu mutant cells could coexist with bacteriophage PP01 in batch culture. Concentrations of the Mu cells and bacteriophage PP01 increased together. The appearance of mutant phage, which showed a different host range among the O157:H7 escape mutants than wild-type PP01, was also detected in the chemostat culture. Thus, coevolution of phage and E. coli O157:H7 proceeded as a mutual arms race in chemostat continuous culture.

Citing Articles

Factors Affecting Phage-Bacteria Coevolution Dynamics.

Jdeed G, Kravchuk B, Tikunova N Viruses. 2025; 17(2).

PMID: 40006990 PMC: 11860743. DOI: 10.3390/v17020235.


Isolation and Characterization of Novel O157:H7 Phage SPEC13 as a Therapeutic Agent for Infections In Vitro and In Vivo.

Islam M, Fan J, Suzauddula M, Nime I, Pan F Biomedicines. 2024; 12(9).

PMID: 39335549 PMC: 11428821. DOI: 10.3390/biomedicines12092036.


Viral plasticity facilitates host diversity in challenging environments.

Bonachela J Nat Commun. 2024; 15(1):7473.

PMID: 39209841 PMC: 11362530. DOI: 10.1038/s41467-024-51344-3.


Microfluidic Ecology Unravels the Genetic and Ecological Drivers of T4r Bacteriophage Resistance in E. coli: Insights into Biofilm-Mediated Evolution.

Nagy K, Valappil S, Phan T, Li S, Der L, Morris R Res Sq. 2024; .

PMID: 38826273 PMC: 11142369. DOI: 10.21203/rs.3.rs-4356333/v1.


Selective bacteriophages reduce the emergence of resistant bacteria in bacteriophage-antibiotic combination therapy.

Azam A, Sato K, Miyanaga K, Nakamura T, Ojima S, Kondo K Microbiol Spectr. 2024; 12(6):e0042723.

PMID: 38695573 PMC: 11237537. DOI: 10.1128/spectrum.00427-23.


References
1.
Carlton R . Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz). 1999; 47(5):267-74. View

2.
Alisky J, Iczkowski K, Rapoport A, Troitsky N . Bacteriophages show promise as antimicrobial agents. J Infect. 1998; 36(1):5-15. DOI: 10.1016/s0163-4453(98)92874-2. View

3.
Park S, Shimamura I, Fukunaga M, Mori K, Nakai T . Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol. 2000; 66(4):1416-22. PMC: 92002. DOI: 10.1128/AEM.66.4.1416-1422.2000. View

4.
Magnuson B, Davis M, Hubele S, Austin P, Kudva I, Williams C . Ruminant gastrointestinal cell proliferation and clearance of Escherichia coli O157:H7. Infect Immun. 2000; 68(7):3808-14. PMC: 101652. DOI: 10.1128/IAI.68.7.3808-3814.2000. View

5.
Sulakvelidze A, Alavidze Z, Morris Jr J . Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45(3):649-59. PMC: 90351. DOI: 10.1128/AAC.45.3.649-659.2001. View